Laurus Labs Limited — Investor Meet, 28-01-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Laurus Labs reported strong Q3 FY26 with revenues of Rs. 1,778 Cr (up 26%) and a 27% EBITDA margin. 9-month revenues hit Rs. 5,001 Cr (up 30%), with PAT soaring 388%. Generics grew 37% in Q3, fueled by ARV volumes and new launches, a trend expected to sustain. CDMO showed over 50% 9-month growth, with Q3 softer due to delivery phasing, but Q4 and FY27 are set for strong commercial supplies. Major CAPEX continues for peptides, ADCs, and gene therapy. ROCE improved to 18.5%. Management is confident in future growth, strategically focusing on high-value CDMO while avoiding large-scale MAB and sterile manufacturing. Confident outlook.